Vykuntaraju K Gowda, Halima Simin, Uddhava V Kinhal, G V Basavaraja, K S Sanjay
{"title":"Cannabidiol in Drug-Resistant Epilepsy (DRE) in Children: A Retrospective Study.","authors":"Vykuntaraju K Gowda, Halima Simin, Uddhava V Kinhal, G V Basavaraja, K S Sanjay","doi":"10.1007/s13312-025-00075-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe the effectiveness and tolerability of cannabidiol (CBD) in children with drug-resistant epilepsy (DRE).</p><p><strong>Methods: </strong>Records of children with DRE who received CBD for at least six months were reviewed. Reduction in seizure frequency [complete (> 90%), partial (30-90%), no response (< 30%)], parent reported adverse effects and discontinuation of CBD, if any, were noted.</p><p><strong>Results: </strong>Records of 50 children with DRE (Lennox-Gastaut syndrome 32, Dravet syndrome 4, and Tuberous sclerosis complex 2), mean (SD) age 7.8 (4.3) years were reviewed. Complete, partial, and no response to CBD was seen in 10, 18 and 14 children; 8 became seizure-free. Eight children discontinued treatment due to lack of efficacy (n = 4), by increased adverse effects (n = 3) and aggravation of seizures (n = 1). Adverse effects were noted in 22 (44%), none required hospitalization.</p><p><strong>Conclusion: </strong>Cannabidiol is a useful and safe add-on drug in children with DRE.</p>","PeriodicalId":13291,"journal":{"name":"Indian pediatrics","volume":" ","pages":"501-505"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13312-025-00075-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To describe the effectiveness and tolerability of cannabidiol (CBD) in children with drug-resistant epilepsy (DRE).
Methods: Records of children with DRE who received CBD for at least six months were reviewed. Reduction in seizure frequency [complete (> 90%), partial (30-90%), no response (< 30%)], parent reported adverse effects and discontinuation of CBD, if any, were noted.
Results: Records of 50 children with DRE (Lennox-Gastaut syndrome 32, Dravet syndrome 4, and Tuberous sclerosis complex 2), mean (SD) age 7.8 (4.3) years were reviewed. Complete, partial, and no response to CBD was seen in 10, 18 and 14 children; 8 became seizure-free. Eight children discontinued treatment due to lack of efficacy (n = 4), by increased adverse effects (n = 3) and aggravation of seizures (n = 1). Adverse effects were noted in 22 (44%), none required hospitalization.
Conclusion: Cannabidiol is a useful and safe add-on drug in children with DRE.
期刊介绍：
The general objective of Indian Pediatrics is "To promote the science and practice of Pediatrics." An important guiding principle has been the simultaneous need to inform, educate and entertain the target audience. The specific key objectives are:
-To publish original, relevant, well researched peer reviewed articles on issues related to child health.
-To provide continuing education to support informed clinical decisions and research.
-To foster responsible and balanced debate on controversial issues that affect child health, including non-clinical areas such as medical education, ethics, law, environment and economics.
-To achieve the highest level of ethical medical journalism and to produce a publication that is timely, credible and enjoyable to read.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
